By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment Bank Leerink Swann this week upgraded its rating on Bio-Rad Laboratories' stock from "market perform" to "outperform," citing a favorable trend for the firm's diagnostics business over the immediate term. The bank also placed a 12-month valuation range of between $107 and $114 on the stock. Bio-Rad closed Wednesday, the day the note was issued, at $98.75.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.